EUVIMEDEUVIMED entdecken
FallberichtLeserbriefOpen Access · CC BY-NC-ND 4.0

Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis

Jerry Fu, Twan Sia, Rachel Solecki, Shibani Mallik, Raisa Khuda, Madison Headen, Leeon Bacchus, Michelle Zheng, Tanvi Telukunta, Saad Shami, Stanley Liu, Sripad Sureshbabu und 9 weitere

The Journal of Allergy and Clinical Immunology: In Practice · 2024

DOI: 10.1016/j.jaip.2024.02.031 ↗

Kurz gefasst

Fallbericht in der Zeitschrift The Journal of Allergy and Clinical Immunology: In Practice, 2024. Verfasst von Jerry Fu und 20 weiteren Autor:innen. Beteiligte Einrichtung: Boston Specialists, Boston, Mass. Hauptthemen laut MEDLINE: Duodenitis, Eosinophilia, Gastritis. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Eosinophilic gastrointestinal diseases (EGIDs) are chronic inflammatory diseases characterized by eosinophilic invasion of the gastrointestinal tract. Patients with noneosinophilic esophagitis (EoE) EGIDs commonly present with abdominal pain, nausea, and other gastrointestinal symptoms.1 Current accepted histologic cutoffs for eosinophilic gastritis (EoG) and duodenitis (EoD) are 30 peak eosinophils or greater per high-power field (eos/hpf) in at least 5 hpfs in the gastric body or antrum and 30 eos/hpf or greater in at least 3 hpf in the duodenum, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DuodenitisEosinophiliaGastritisFemaleHumansEnteritisHeterocyclic Compounds, 3-RingRemission InductionTreatment OutcomeMiddle Aged

Substanzen

Heterocyclic Compounds, 3-Ringupadacitinib

Autor:innen und Institutionen

  • Boston Specialists, Boston, Mass.
  • School of Medicine, Stanford University, Stanford, Calif.
  • School of Medicine, University of Connecticut, Storrs, Conn.
  • Department of Pathology & Lab Services, Carney Hospital, Dorchester, Mass.
  • Boston Specialists, Boston, Mass. Electronic address: drjohnleung@bfac.org.

Zitieren

APA

Fu, J., Sia, T., Solecki, R., Mallik, S., Khuda, R., Headen, M., Bacchus, L., Zheng, M., Telukunta, T., Shami, S., Liu, S., Sureshbabu, S., Love, K., Roby, A., McDonald, P., Jiang, Y., Narayanan, D. H., Cunningham, E., Matmatte, A. S., …, & Leung, J. (2024). Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis. The Journal of Allergy and Clinical Immunology: In Practice. https://doi.org/10.1016/j.jaip.2024.02.031

Vancouver

Fu J, Sia T, Solecki R, Mallik S, Khuda R, Headen M, et al. Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis. The Journal of Allergy and Clinical Immunology: In Practice. 2024. doi:10.1016/j.jaip.2024.02.031

BibTeX
@article{Fu2024,
  author = {Fu, Jerry and Sia, Twan and Solecki, Rachel and Mallik, Shibani and Khuda, Raisa and Headen, Madison and Bacchus, Leeon and Zheng, Michelle and Telukunta, Tanvi and Shami, Saad and Liu, Stanley and Sureshbabu, Sripad and Love, Kathleen and Roby, Alyssa and McDonald, Paige and Jiang, Yuting and Narayanan, Dharaneswari Hari and Cunningham, Evan and Matmatte, Amina Sara and Tan, Puay Eng and Leung, John},
  title = {Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis},
  journal = {The Journal of Allergy and Clinical Immunology: In Practice},
  year = {2024},
  doi = {10.1016/j.jaip.2024.02.031}
}
Kostenlos starten →